



September 10, 2015

PDL BioPharma to Present at the 6th Annual Credit Suisse US Small & Mid Cap Conference

INCLINE VILLAGE, Nev., Sept. 10, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the 6th Annual Credit Suisse US Small & Mid Cap Conference in New York City next week. The group presentation will occur on Thursday, September 17, 2015 at 11:30 a.m. EDT.

The conference format includes one-on-one meetings and a group presentation. The corporate presentation will not be webcast, but PDL's investor presentation will be accessible via the Investor Relations section of the company's website at www.pdl.com.

About PDL BioPharma

PDL manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. To acquire new income generating assets, PDL provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. PDL has invested approximately \$830 million to date. PDL evaluates its investments based on the quality of the income generating assets and potential returns on investment. PDL is currently focused on intellectual property asset management, acquiring new income generating assets and maximizing value for its shareholders. PDL was founded in 1986 and is headquartered in Incline Village, Nevada.

For more information, please visit www.pdl.com.

PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Logo - <http://photos.prnewswire.com/prnh/20110822/SF55808LOGO>

To view the original version on PR Newswire, visit:<http://www.prnewswire.com/news-releases/pdl-biopharma-to-present-at-the-6th-annual-credit-suisse-us-small--mid-cap-conference-300140423.html>

SOURCE PDL BioPharma, Inc.

News Provided by Acquire Media